Clinical Trials on Neuroendocrine Prostate Cancer

Total 55611 results

CureVac

Completed

Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease

Hormonal Refractory Prostate Cancer

Germany, Italy
Burzynski Research Institute

Withdrawn

Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer

Stage IV Prostate Cancer

United States
Tianjin Medical University Cancer Institute and...
Peking University First Hospital; The Affiliated Nanjing Drum Tower Hospital... and other collaborators

Unknown

Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer (CRYO-PCA-IV)

Stage IV Prostate Cancer

China
US Oncology Research
Eli Lilly and Company; Oregon Health and Science University

Completed

Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

Androgen-independent Prostate Cancer

United States
Temple University

Completed

Prostate Cancer Education in African American Men

Prostate Cancer Screening Decision

United States
Exelixis

Terminated

Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms | Prostate Cancer | Castration Resistant Prostate Cancer

United States
Infinity Pharmaceuticals, Inc.

Completed

A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer (IPI-504-04)

Prostatic Neoplasms | Prostate Cancer | Cancer of the Prostate

United States
Agennix

Completed

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

Prostate Cancer | Hormone Refractory Prostate Cancer

United States, United Kingdom, France, Italy, Israel, Germany, Hungary, Argentina, Russian Federation, Belgium, Croatia, Netherlands, Peru, Poland, Spain
AstraZeneca

Completed

Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

Non-metastatic Prostate Cancer

United States, Canada
Veeda Oncology
Bayer

Terminated

PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

Hormone Refractory Prostate Cancer

United States
Zhengzhou University
The First Affiliated Hospital of Zhengzhou University; Xinyang Central Hospital and other collaborators

Unknown

Radiotherapy vs Observation for CRPC

Hormone Refractory Prostate Cancer

China
CytoVac A/S

Completed

Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy (ALECSAT)

Hormone-refractory Prostate Cancer

Denmark
University of Florida
CureVac

Terminated

RNActive®-Derived Therapeutic Vaccine

Hormone Refractory Prostate Cancer

United States
National University Hospital, Singapore

Completed

A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients

Hormone-Refractory Prostate Cancer

Singapore
CytRx

Completed

Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer (PROACT)

Hormone Refractory Prostate Cancer

United States
AstraZeneca

Completed

(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer (Capri)

Non-Metastatic Prostate Cancer

Czech Republic, Italy, South Africa, United Kingdom, Germany, Poland, Netherlands, Austria, Belgium, Hungary, Israel, Portugal, Mexico, Spain, Australia, Ireland
Ascenta Therapeutics

Completed

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

Hormone Refractory Prostate Cancer

United States, Russian Federation
Merrion Pharmaceuticals, LLC

Completed

Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients

Hormone-Refractory Prostate Cancer

United States, Estonia, Latvia
Fudan University

Not yet recruiting

Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment (CHAMPION)

Metastatic Prostate Cancer | Castration-Sensitive Prostate Cancer

China
Modra Pharmaceuticals

Completed

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

United States, Germany, Hungary, Poland, Russian Federation, Czechia
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Completed

COMbination of Bipolar Androgen Therapy and Nivolumab (COMBAT-CRPC)

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

Recurrent Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Stage IV Prostate Cancer

United States
Jules Bordet Institute

Withdrawn

Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management (ProsPERo)

Prostate Cancers
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer

Prostate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Testosterone Greater Than 150 ng/dL

United States
Mayo Clinic

Not yet recruiting

Evaluating Changes in Quality of Life After Near Margin-less Adaptive Radiation Therapy Compared to Standard Stereotactic Ablative Body Radiotherapy in Localized Prostate Cancer

Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Localized Prostate Adenocarcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Prostate Adenocarcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

United States, Canada
Jonsson Comprehensive Cancer Center
Janssen Scientific Affairs, LLC

Not yet recruiting

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial (HEATWAVE)

Prostate Adenocarcinoma | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8

United States
National Cancer Institute (NCI)

Recruiting

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

Prostate Adenocarcinoma | Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8

United States
Mayo Clinic

Recruiting

Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors

Prostate Cancer | Prostate Adenocarcinoma | Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8

United States
Praful Ravi, MB BCHir, MRCP
Eli Lilly and Company; Bayer

Active, not recruiting

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Non-metastatic Prostate Cancer

United States
Hinova Pharmaceuticals USA, Inc.

Active, not recruiting

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

Germany, Spain, Denmark, France, United Kingdom, Russian Federation, Poland, Australia, Italy, Netherlands, United States, Finland, Canada, Austria
Massachusetts General Hospital

Completed

Cabozantinib in Advanced Solid Malignancies

Lung Cancer | Solid Tumor (Not Breast or Prostate Cancers)

United States
Amgen

Completed

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Carcinoma | Cancer | Prostate Cancer | Tumors | Castrate-Resistant Prostate Cancer

United States, Canada, Poland, Hungary, Finland, Mexico
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Active, not recruiting

Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer (PCW)

Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer

United States, Guam
University of Colorado, Denver

Active, not recruiting

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

Recurrent Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer

Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | PSA Level Five to Ten | PSA Level Less Than Five | PSA Level Ten to Fifty

United States
Shanghai Humantech Biotechnology Co. Ltd
Shanghai Changhai Hospital,The First Affiliated Hospital of Naval Medical...

Recruiting

Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

China
UNICANCER
Bayer

Recruiting

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Prostate Cancer Metastatic

Spain, France, Ireland, Belgium
David M Lubaroff
United States Department of Defense

Completed

Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer (APP22)

Hormone Refractory Prostate Cancer

United States
FutureChem

Completed

[177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer.

Metastatic Castration-resistant Prostate Cancer

Korea, Republic of
Azienda Ospedaliero-Universitaria Careggi

Completed

Predictive fActors for toleraNce to Taxane Based CHemotherapy In Older adultS Affected by mEtastatic Prostate Cancer (ANCHISES)

Metastatic Prostate Cancer | Elderly Patients

Italy
Sanofi

Completed

Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)

Prostate Cancer Metastatic

United Kingdom, Austria, Belgium, Czechia, France, Germany, Greece, Iceland, Ireland, Italy, Netherlands, Norway, Spain
Hinova Pharmaceuticals Inc.

Completed

A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch

Metastatic Castration Resistant Prostate Cancer

China
Effector Therapeutics

Completed

An Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)

Castrate-resistant Prostate Cancer (CRPC)

United States
Centro Nacional de Investigaciones Oncologicas...

Unknown

PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate. (PROSABI)

Advanced Prostate Cancer | Abiraterone ACetate

Spain
Memorial Sloan Kettering Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

Metastatic Castration-Resistant Prostate Cancer

United States
Bellicum Pharmaceuticals
M.D. Anderson Cancer Center; The University of Texas Health Science Center,... and other collaborators

Completed

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

Castrate Resistant Prostate Cancer (CRPC)

United States
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

Metastatic Castration-Resistant Prostate Cancer

United States
Innocrin Pharmaceutical

Completed

A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

Castration-resistant Prostate Cancer | CRPC

United States, Greece, Switzerland, United Kingdom
National Cancer Institute (NCI)

Completed

A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)

Prostate Cancer | Metastatic Castrate Resistant Prostate Cancer

United States

Clinical Trials on Neuroendocrine Prostate Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations